80 related articles for article (PubMed ID: 18092831)
1. Homology modeling of wild-type, D516V, and H526L Mycobacterium tuberculosis RNA polymerase and their molecular docking study with inhibitors.
Josa D; da Cunha EF; Ramalho TC; Souza TC; Caetano MS
J Biomol Struct Dyn; 2008 Feb; 25(4):373-6. PubMed ID: 18092831
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling of Mycobacterium tuberculosis DNA gyrase and its molecular docking study with gatifloxacin inhibitors.
da Cunha EE; Barbosa EF; Oliveira AA; Ramalho TC
J Biomol Struct Dyn; 2010 Apr; 27(5):619-25. PubMed ID: 20085379
[TBL] [Abstract][Full Text] [Related]
3. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
Gill SK; Garcia GA
Tuberculosis (Edinb); 2011 Sep; 91(5):361-9. PubMed ID: 21704562
[TBL] [Abstract][Full Text] [Related]
4. Use of a high-density DNA probe array for detecting mutations involved in rifampicin resistance in Mycobacterium tuberculosis.
Sougakoff W; Rodrigue M; Truffot-Pernot C; Renard M; Durin N; Szpytma M; Vachon R; Troesch A; Jarlier V
Clin Microbiol Infect; 2004 Apr; 10(4):289-94. PubMed ID: 15059116
[TBL] [Abstract][Full Text] [Related]
5. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
Kurabachew M; Lu SH; Krastel P; Schmitt EK; Suresh BL; Goh A; Knox JE; Ma NL; Jiricek J; Beer D; Cynamon M; Petersen F; Dartois V; Keller T; Dick T; Sambandamurthy VK
J Antimicrob Chemother; 2008 Oct; 62(4):713-9. PubMed ID: 18587134
[TBL] [Abstract][Full Text] [Related]
6. Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis.
Park YK; Kim BJ; Ryu S; Kook YH; Choe YK; Bai GH; Kim SJ
Int J Tuberc Lung Dis; 2002 Feb; 6(2):166-70. PubMed ID: 11931418
[TBL] [Abstract][Full Text] [Related]
7. [RNA polymerase-rifamycin. A molecular model of inhibition].
Chertov OIu; Obukhov AN; Lipkin VM
Bioorg Khim; 1983 May; 9(5):633-40. PubMed ID: 6207842
[TBL] [Abstract][Full Text] [Related]
8. Recent trends in rifamycin research.
Lal R; Lal S
Bioessays; 1994 Mar; 16(3):211-6. PubMed ID: 7513153
[TBL] [Abstract][Full Text] [Related]
9. Identification of new antibacterial targets in RNA polymerase of Mycobacterium tuberculosis by detecting positive selection sites.
Wang Q; Xu Y; Gu Z; Liu N; Jin K; Li Y; Crabbe MJC; Zhong Y
Comput Biol Chem; 2018 Apr; 73():25-30. PubMed ID: 29413813
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis.
Heep M; Rieger U; Beck D; Lehn N
Antimicrob Agents Chemother; 2000 Apr; 44(4):1075-7. PubMed ID: 10722516
[TBL] [Abstract][Full Text] [Related]
11. Lost in transcription--inhibition of RNA polymerase.
Haebich D; von Nussbaum F
Angew Chem Int Ed Engl; 2009; 48(19):3397-400. PubMed ID: 19294713
[TBL] [Abstract][Full Text] [Related]
12. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910.
de Jonge MR; Koymans LH; Guillemont JE; Koul A; Andries K
Proteins; 2007 Jun; 67(4):971-80. PubMed ID: 17387738
[TBL] [Abstract][Full Text] [Related]
13. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis.
Siu GK; Zhang Y; Lau TC; Lau RW; Ho PL; Yew WW; Tsui SK; Cheng VC; Yuen KY; Yam WC
J Antimicrob Chemother; 2011 Apr; 66(4):730-3. PubMed ID: 21393153
[TBL] [Abstract][Full Text] [Related]
14. Rifamycin-mode of action, resistance, and biosynthesis.
Floss HG; Yu TW
Chem Rev; 2005 Feb; 105(2):621-32. PubMed ID: 15700959
[No Abstract] [Full Text] [Related]
15. A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis.
Shen H; Wang F; Zhang Y; Huang Q; Xu S; Hu H; Yue J; Wang H
FEBS J; 2009 Jan; 276(1):144-54. PubMed ID: 19032598
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship studies of new rifamycins containing l-amino acid esters as inhibitors of bacterial RNA polymerases.
Czerwonka D; Domagalska J; Pyta K; Kubicka MM; Pecyna P; Gajecka M; Przybylski P
Eur J Med Chem; 2016 Jun; 116():216-221. PubMed ID: 27061985
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of anthranilate synthase component I (TrpE) from Mycobacterium tuberculosis H37Rv.
Lin X; Xu S; Yang Y; Wu J; Wang H; Shen H; Wang H
Protein Expr Purif; 2009 Mar; 64(1):8-15. PubMed ID: 18952181
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling of Mycobacterium tuberculosis dUTpase: docking and catalytic mechanism studies.
Ramalho TC; Caetano MS; Josa D; Luz GP; Freitas EA; da Cunha EF
J Biomol Struct Dyn; 2011 Jun; 28(6):907-17. PubMed ID: 21469751
[TBL] [Abstract][Full Text] [Related]
19. Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins.
Artsimovitch I; Vassylyeva MN; Svetlov D; Svetlov V; Perederina A; Igarashi N; Matsugaki N; Wakatsuki S; Tahirov TH; Vassylyev DG
Cell; 2005 Aug; 122(3):351-63. PubMed ID: 16096056
[TBL] [Abstract][Full Text] [Related]
20. The three-dimensional structures of the Mycobacterium tuberculosis dihydrodipicolinate reductase-NADH-2,6-PDC and -NADPH-2,6-PDC complexes. Structural and mutagenic analysis of relaxed nucleotide specificity.
Cirilli M; Zheng R; Scapin G; Blanchard JS
Biochemistry; 2003 Sep; 42(36):10644-50. PubMed ID: 12962488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
